apart from the active substance

DRUG3 trials

Sponsors

Universitaetsklinikum Tuebingen AöR, Universität Zürich - Klinik für Neonatologie, Charite Universitaetsmedizin Berlin KöR, Epygenix Therapeutics Inc.

Conditions

Dravet syndromePost-COVID-19 syndrome without (PCS) or with (PCS/CFS) fulfillment of myalgic encephalomyelitis/chronic fatique syndrome (ME/CFS) criteriaRetinopathy of prematurity

Phase 2

Oral propranolol for prevention of threshold retinopathy of prematurity

RecruitingCTIS2024-511338-10-01

Universitaetsklinikum Tuebingen AöR, Universität Zürich - Klinik für NeonatologieRetinopathy of prematurity

Start: 2024-07-24Target: 100Updated: 2025-09-02

A parallel-group treatment, phase 2a, double-blind, placebo-controlled 2-arm study to show improvement of physical function in SF-36 (SF-36-PF) in participants treated with Vericiguat compared to placebo tablets participants with post-COVID-19 syndrome without (PCS) or with (PCS/CFS) fulfillment of ME/CFS criteria - VERI-LONG

Active, not recruitingCTIS2024-517713-33-00

Charite Universitaetsmedizin Berlin KöRPost-COVID-19 syndrome without (PCS) or with (PCS/CFS) fulfillment of myalgic encephalomyelitis/chronic fatique syndrome (ME/CFS) criteria

Start: 2023-05-31Target: 104Updated: 2025-06-11

Phase 3

A 20-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of EPX-100 (Clemizole Hydrochloride) as Adjunctive Therapy in Children and Adult Participants with Dravet Syndrome (ARGUS Trial)

RecruitingCTIS2024-518628-57-00

Epygenix Therapeutics Inc.Dravet syndrome

Start: 2023-08-01Target: 32Updated: 2026-01-27